Avicidin

Avicidin

An investigational radioimmunotherapeutic agent for treating advanced therapeutically refractive cancers of the colon, ovarian and prostate, which delivers high-dose RT to metastatic tumours, while minimising exposure of normal tissues, especially bone marrow. Avicidin was discontinued in phase-II trials due to a high incidence of unacceptable diarrhea, which was atributed to cross-reactivity of the Avicidin anti-Epcam antibody with the intestine.
References in periodicals archive ?
One of these is a full-length IgG specific for EpCAM (a marker of colorectal cancer) developed as the drug Avicidin by NeoRx and Monsanto.